As consumers seek ways to determine authentic EVOO from the fake, Bellucci, headquartered in Grosseto, Italy, is offering a multi-pronged solution: traceability and sophisticated tasting skills. The company offers precise, detailed information to empower customers in choosing true EVOO products, while ensuring the authenticity of Bellucci EVOO at all levels of production.
Bellucci keeps digital track of each olive grower’s contribution throughout the cooperative milling and bottling process, so any bottle of Bellucci EVOO can be traced to its origin in rural Italy. In addition to its traceability function, the Bellucci App teaches users how to evaluate for freshness and taste for flavors unique to EVOO. Advanced instruction in discerning flavor nuances based on harvests, regions and olive cultivars offers an experience of EVOO as an expression of terroir.
The value of the Bellucci App in communicating with consumers was recognized at the 2015 Anuga International Food Show. Bellucci has also received several awards for its line of EVOO. The Los Angeles International Extra Virgin Olive Oil Competition awarded silver medals to both the 2016 Toscano PGI Organic and the 2015 100% Italian Organic, and the 2016 harvest of 100% Italian won a gold medal at this year’s New York International Olive Oil Competition. A brand less than three years old, Bellucci is already being widely recognized for its flavor and contribution to the industry.
To view the multimedia release go to:
http://www.multivu.com/players/English/7716352-bellucci-olive-oil-consumer-education-app/
The Energy Globe World Award goes to Nicaragua! With a happy “Muchas Gracias”, Martha Veronica Rocha received the 13 kg bronze statue for her organization FUPROSOMUNIC in the studio of the Austrian Broadcasting Corporation Salzburg. Salzburg Governor Wilfried Haslauer, Mayor Heinz Schaden, Cardinal of the Roman Catholic Church Peter Turkson and Energy Globe Founder Wolfgang Neumann presented the award. Austria also excelled as a category winner in “Fire.” Wolfgang Neumann: “These projects are a strong signal – they show the world that our environmental problems can be solved.”
To view the Multimedia News Release, go to http://www.multivu.com/mnr/64995-energy-globe-world-award-solar-women
Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced it has received U.S. Food and Drug Administration (FDA) clearance for the ClearSight system.
The ClearSight system is a noninvasive monitor that provides clinicians access to valuable blood volume and blood flow information for patients at moderate or high risk of post-surgical complications, in whom invasive monitoring would not be used.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7256451-edwards-fda-clearance-for-noninvasive-hemodynamic-monitoring-system/
Johnson & Johnson today honors the winners of the 2012 Dr. Paul Janssen Award for Biomedical Research in a ceremony and scientific symposium at the New York Academy of Sciences in New York, NY. Victor Ambros, Ph.D., of the University of Massachusetts Medical School, and Gary Ruvkun, Ph.D., of Massachusetts General Hospital and Harvard Medical School, received the award for their collaborative discovery of microRNAs (miRNAs) as central regulators of gene expression and development, and will share a $100,000 prize.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58019-johnson-and-johnson-jnj-2012-dr-paul-janssen-award-for-biomedical-research
Oliver Conrad and Gian Klainguit, a directing team with DUCK developed the short, Dixie Trixi within 48 hours and received top honors at the recent Stuttgart Festival of Animated Film.
For more information, visit http://www.trustcollective.com/portfolio/content/duck_dixietrixi.htm
The all-new 2016 Honda Pilot SUV made its global premiere at the 2015 Chicago Auto Show. Reengineered and redesigned in America, the 2016 Honda Pilot delivers more family-friendly utility, more advanced technology and more premium attributes and amenities than ever before, boasting class-leading safety features, fuel efficiency and confident driving dynamics in a thoroughly modern, stylish and sophisticated new package.
The all-new 2016 Pilot, launching at Honda dealerships nationwide this summer, is the third generation of Honda’s three-row midsize SUV to be designed, developed and manufactured in America. Reinforcing 2015 as the “Year of Honda,” Pilot further strengthens Honda’s SUV/CUV triple threat by joining the exceptionally well received 2015 CR-V (2015 Motor Trend SUV of the Year) and greatly anticipated new 2016 HR-V.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7415551-chicago-auto-show/
Corindus Vascular Robotics, a leading developer of precision vascular robotics, today announced FDA 510(k) clearance has been granted for the CorPath 200 System to be used in percutaneous coronary interventions (PCI). The technology is now approved in the United States to assist interventional cardiologists in performing PCI, a procedure to restore blood flow to blocked arteries in patients with coronary artery disease (CAD).
“We are pleased to have received clearance from the FDA for the world’s first system designed for robotic-assisted PCI procedures,” said David M. Handler, President and CEO of Corindus Vascular Robotics. “This is an important milestone for interventional cardiology as we take the next step in transforming the way these procedures are performed in the future. The CorPath System offers hospitals the opportunity to bring robotic-assisted technology benefits to their coronary patients and their physicians.”
To view Multimedia News Release, go to http://www.multivu.com/mnr/57343-corindus-vascular-robotics-wins-fda-510k-clearance-for-corpath-200-system
Ascensia Diabetes Care today announced the availability of the CONTOUR®NEXT ONE blood glucose monitoring system (BGMS) in the United Kingdom, one of the next steps in the evolution of self-monitoring of blood glucose. As part of the system, the CONTOUR®NEXT ONE meter and CONTOUR®DIABETES app seamlessly connect, which makes capturing blood glucose results effortless for people with diabetes. The system enables patterns and trends to be revealed that can help people understand their diabetes, and may help to improve diabetes management.
The system features an easy-to-use wireless-enabled smart meter that links to a smart mobile device via Bluetooth® connectivity. The CONTOUR®NEXT ONE meter gives immediate feedback and also seamlessly connects to the CONTOUR®DIABETES app, which collects, stores and analyses patient blood glucose results received from the meter. The app combines these results with other data recorded by the user, to provide detailed information about their condition that can help them understand how their everyday lives may impact their blood glucose readings, including alerts for critical high or critical low readings. Through the app, meter users can also share with their healthcare professional the reports of their blood glucose results and patterns, either in advance or on the day of their appointment, helping to create more informed discussions.
To view the multimedia release go to:
http://www.multivu.com/players/uk/7954951-contour-next-one-bgms-ascensia/
https://www.amazon.com/Ingenious-TG633-Construction-ThinkGizmos-batteries/dp/B01ANVU7R6
I received this product in exchange for my unbiased review
Thank you for watching!
If you enjoyed this video please give it a Thumbs Up and Subscribe to my channel for more product review videos.
Following the unprecedented Gore REDUCE Clinical Study conclusion that closure of patent foramen ovale (PFO) can prevent recurrent ischemic strokes, W. L. Gore & Associates, Inc. (Gore) has received approval from the U.S. Food and Drug Administration (FDA) for an expanded indication for its GORE® CARDIOFORM Septal Occluder. The device, already approved for closure of atrial septal defects (ASDs) up to 17 mm, is now also approved for the closure of PFO to reduce the risk of recurrent ischemic stroke in certain patients.*
To view the multimedia release go to:
https://www.multivu.com/players/English/8301551-gore-cardioform-septal-occluder-fda-approval/
Clayton Homes is announcing that its homebuilding facility in Rutledge, Tenn., has received ISO 14001 Certification, making the company the first homebuilder among the members of the Manufactured Housing Institute to receive this achievement in the United States.*
The ISO 14001 certification is awarded to buliding facilities that have instituted international measures designed to reduce the cost of waste management and save energy consumption. The implementation of the ISO standard at the Clayton Rutledge facility will result in reduced waste, lowered consumption of energy and the promotion of the recycling of building materials, which endorses environmentally friendly operating procedures. Clayton Homes is leading the American homebuilding industry by example, putting the well being of its team members and the environment first. The continued cost savings of these green practices are one of the reasons why Clayton Homes is able to provide homeowners with affordable, smart homes.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7448251-clayton-homes-iso-certification/
Studies show that more than two-thirds of aesthetically-oriented consumers are bothered by submental fullness, or “double chin.” And with social media profile images becoming more important than ever, there is interest in looking one’s best.
Submental fullness due to fat beneath the chin can impact a broad range of both men and women and because the condition can be genetic and resistant to diet and exercise. But there’s KYBELLA®, the first and only FDA-approved injectable treatment that is available by prescription only, that has been proven to improve the appearance of moderate to severe fat beneath the chin by physically destroying fat cells in the treatment area. In two pivotal clinical studies for KYBELLA®, reductions in submental fat volume were observed more frequently in the KYBELLA® treated group of 514 patients compared to the placebo group (508 patients) as measured by both clinician and patient ratings. In addition, visual and emotional impacts of submental fat (happy, bothered, self-conscious, embarrassed, looking older or overweight) were evaluated using a 6-question survey and 79% of 1 and 2-grade composite responders reported satisfaction after 12 weeks post final treatment compared with 33.6% of patients who received placebo.
To view the multimedia release go to:
http://www.multivu.com/players/English/7962051-kybella-injectable-double-chin-treatment-campaign/
